Iceland volcano: Mass of magma pooling beneath ground north of Grindavík indicates imminent eruption

The risk of a volcanic eruption on Iceland's Reykjanes Peninsula is once again growing as magma continues to pool in the area 2.5 miles north of the fishing town of Grindavík, according to the Icelandic Met Office .

Between 318 million and 460 million cubic feet of magma are thought to have accumulated in the same chamber before an eruption on Jan. 14 that sent lava coursing toward Grindavík.The land began rising again following the eruption and continues to inflate as molten rock gathers under the surface, although the rate has slowed in the last few days, according to the IMO statement. This pattern is the same as land movements recorded in the weeks and days preceding the eruption on Jan.

However, temperature and pressure measurements taken from boreholes in Svartsengi could provide a warning that another eruption is on its way.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Mass Spectrometry Imaging Specialist - Newark, New Jersey job with Rutgers HealthNew Jersey’s academic health center, Rutgers Biomedical and Health Sciences (RBHS) takes an integrated approach to educating students, providing clinical care, and conducting research, all with the goal of improving human health.
Source: Nature - 🏆 64. / 68 Read more »

'Mass Chaos': Juvenile, adult shot at gym on Indy's northwest sideIMPD Capt. McCardia described the scene at VASA Fitness as 'mass chaos'
Source: wrtv - 🏆 598. / 51 Read more »

First-Ever CRISPR-Based Therapy Approved for Sickle Cell DiseaseU.S. patients with sickle cell disease now have a novel treatment option: the first-ever CRISPR-based therapy.for use in patients age 12 years and older. In addition to offering hope of relief for people with severe forms of the painful blood disorder, the treatment, called Casgevy, is the world’s first to genetically tweak cells using theAnother gene therapy for sickle cell disease, called Lyfgenia and developed by biotech company bluebird bio, based in Somerville, Mass., was also approved December 8. Getting a green light for the first CRISPR-based medicine is exciting, says David Altshuler, chief scientific officer at Boston-based Vertex Pharmaceuticals, which developed the drug in a joint venture with CRISPR Therapeutics, a company in Cambridge, Mass. But the fact that the drug fills an unmet need for underserved patients is “more compelling to me, personally, than the fact that it’s CRISPR.” , most of them Black or Latino, have sickle cell disease. It is caused by a genetic defect in hemoglobin, the oxygen-carrying protein in red blood cells
Source: ScienceNews - 🏆 286. / 63 Read more »